Arkolith/Insider Trading/ABOS/Form 4

OConnell Daniel Joseph

Chief Executive Officer, DirectorAcumen Pharmaceuticals, Inc. (ABOS) · full profile →Form 4 · filed Jan 7, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$94K
Net Open-Market Flow
-$94K
Transactions
3
3 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 7, 2026Sell(S)38K$1.99$75K620K
Jan 6, 2026Sell(S)5K$1.97$10K658K
Jan 5, 2026Sell(S)5K$1.97$9K663K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-001263) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML